Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label extension of GDC-0853 in systemic lupus erythematosus
2017-001764-37Phase 2Terminated
- Sponsor
- Genentech
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenebrutinib in systemic lupus erythematosus (SLE), sponsored by Genentech. Primary endpoint: Long-term safety of GDC-0853. Started Aug 2017; status: terminated.
02
Drugs
fenebrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2017-001764-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001764-37.